CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice4-Year Results From a Large 2-Institutional Cohort Study
Peter Wenaweser, MD*,
Joost Daemen, MD ,
Marcel Zwahlen, PhD ,
Ron van Domburg, PhD,
Peter Jüni, MD,
Sophia Vaina, MD, PhD,
Gerrit Hellige, MD*,
Keiichi Tsuchida, MD,
Cyrill Morger, MD*,
Eric Boersma, PhD,
Neville Kukreja, MBBS, MRCP,
Bernhard Meier, MD*,
Patrick W. Serruys, MD, PhD and
Stephan Windecker, MD*,*
* Department of Cardiology, University of Bern, Bern, Switzerland
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
Manuscript received March 18, 2008;
revised manuscript received June 30, 2008,
accepted July 1, 2008.
* Reprint requests and correspondence: Dr. Stephan Windecker, Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland (Email: stephan.windecker{at}insel.ch).
Objectives: We sought to determine the risk of late stent thrombosis (ST) during long-term follow-up beyond 3 years, searched for predictors, and assessed the impact of ST on overall mortality.
Background: Late ST was reported to occur at an annual rate of 0.6% up to 3 years after drug-eluting stent (DES) implantation.
Methods: A total of 8,146 patients underwent percutaneous coronary intervention with a sirolimus-eluting stent (SES) (n = 3,823) or paclitaxel-eluting stent (PES) (n = 4,323) and were followed up to 4 years after stent implantation. Dual antiplatelet treatment was prescribed for 6 to 12 months.
Results: Definite ST occurred in 192 of 8,146 patients with an incidence density of 1.0/100 patient-years and a cumulative incidence of 3.3% at 4 years. The hazard of ST continued at a steady rate of 0.53% (95% confidence interval [CI]: 0.44 to 0.64) between 30 days and 4 years. Diabetes was an independent predictor of early ST (hazard ratio [HR]: 1.96; 95% CI: 1.18 to 3.28), and acute coronary syndrome (HR: 2.21; 95% CI: 1.39 to 3.51), younger age (HR: 0.97; 95% CI: 0.95 to 0.99), and use of PES (HR: 1.67; 95% CI: 1.08 to 2.56) were independent predictors of late ST. Rates of death and myocardial infarction at 4 years were 10.6% and 4.6%, respectively.
Conclusions: Late ST occurs steadily at an annual rate of 0.4% to 0.6% for up to 4 years. Diabetes is an independent predictor of early ST, whereas acute coronary syndrome, younger age, and PES implantation are associated with late ST.
Key Words: drug-eluting stent • mortality • stent thrombosis
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | ARC = Academic Research Consortium | | ASA = acetylsalicylic acid | | BMS = bare-metal stent(s) | | CI = confidence interval | | DES = drug-eluting stent(s) | | MACE = major adverse cardiac event | | MI = myocardial infarction | | PES = paclitaxel-eluting stent(s) | | SES = sirolimus-eluting stent(s) | | ST = stent thrombosis | | TIMI = Thrombolysis In Myocardial Infarction |
|
This article has been cited by other articles:
|
|
|
|
 
U. Stenestrand, S. K. James, J. Lindback, O. Frobert, J. Carlsson, F. Schersten, T. Nilsson, B. Lagerqvist, and for the SCAAR/SWEDEHEART study group
Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term of follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J.,
November 10, 2009;
(2009)
ehp424v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, et al.
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
Eur. Heart J.,
November 2, 2009;
30(22):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis
A Generation 2.5 Drug-Eluting Stent?
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
986 - 988.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wijns and P. Kolh
Appropriate myocardial revascularization: a joint viewpoint from an interventional cardiologist and a cardiac surgeon
Eur. Heart J.,
September 2, 2009;
30(18):
2182 - 2185.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Roe, A. Y. Chen, C. P. Cannon, S. Rao, J. Rumsfeld, D. J. Magid, R. Brindis, L. W. Klein, W. B. Gibler, E. M. Ohman, et al.
Temporal Changes in the Use of Drug-Eluting Stents for Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention From 2006 to 2008: Results From the Can Rapid risk stratification of Unstable angina patients Supress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (ACTION-GWTG) Registries
Circ Cardiovasc Qual Outcomes,
September 1, 2009;
2(5):
414 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Khattab, C. W. Hamm, J. Senges, R. Toelg, V. Geist, T. Bonzel, M. Kelm, B. Levenson, C. A. Nienaber, T. Pfannebecker, et al.
Sirolimus-Eluting Stent Treatment at High-Volume Centers Confers Lower Mortality at 6-Month Follow-Up: Results From the Prospective Multicenter German Cypher Registry
Circulation,
August 18, 2009;
120(7):
600 - 606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wijns
Late Stent Thrombosis After Drug-Eluting Stent: Seeing Is Understanding
Circulation,
August 4, 2009;
120(5):
364 - 365.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cook and P. Wenaweser
Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
273 - 276.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lasala, D. A. Cox, D. Dobies, K. Baran, W. B. Bachinsky, E. W. Rogers, J. A. Breall, D. H. Lewis, A. Song, R. M. Starzyk, et al.
Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
285 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ormiston and P. W.S. Serruys
Bioabsorbable Coronary Stents
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
255 - 260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Leon, D. J. Allocco, K. D. Dawkins, and D. S. Baim
Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
504 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Brar, M. B. Leon, G. W. Stone, R. Mehran, J. W. Moses, S. K. Brar, and G. Dangas
Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.
J. Am. Coll. Cardiol.,
May 5, 2009;
53(18):
1677 - 1689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J.,
April 2, 2009;
30(8):
916 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
|
|
|
